Pfizer or Enbridge: Only One Gets My Dividend Dollars for the Next 10 Years

Pfizer Inc (PFE) stock rose 3.14% on October 14, outperforming its sector and peers. The increase followed a collaboration announcement with Enodia Therapeutics, upcoming research presentations, and positive earnings revisions. Analysts note technical buy signals but caution about downgrades, COVID-19 revenue declines, and patent expirations. The company's revenue was $62.58B, with a net profit of $7.77B. Analysts' average price target is $29.03.

The Wisconsin DNR issued a notice of violation to Enbridge Energy for alleged environmental infractions during the Line 5 reroute project, citing permit non-compliance and unpermitted construction. The violations span March to September 2026, affecting water, air, and endangered resources. The DNR plans further review and potential legal action. This is separate from Enbridge's obligations under the state Spills Law for a prior incident.

The Wisconsin DNR issued a Notice of Violation against Enbridge for alleged environmental law violations during Line 5 pipeline construction. The DNR cited a 'persistent pattern of non-compliance' with state laws. Clean Wisconsin, involved in a legal case against the project, called for enforcement action. Enbridge has previously paid fines for violations in Wisconsin, including $275,000 for a 2019 spill and $1.1 million for 2008 construction violations.

Wisconsin regulators issued violation notices to Enbridge Energy for alleged unpermitted activities related to the $450M Line 5 pipeline project. The project, which involves a 41-mile reroute, is stalled while regulators enforce environmental protections. Enbridge faces scrutiny for permit violations and unauthorized construction. Meanwhile, NeuVentus is advancing a gas storage project in Texas.

Pfizer (NYSE: PFE) will present data from over 50 studies at IDWeek 2026, showcasing advancements in infectious disease prevention and treatment. Key highlights include Phase 2 and 3 results for next-generation vaccines, such as a 25-valent pneumococcal vaccine and a Lyme disease vaccine. The company also shares real-world data on the effectiveness of its RSV and pneumococcal vaccines.

Pfizer will present data from nursing homes on its RSV vaccine, ABRYSVO, after three seasons. The company will also share updates on its pneumococcal, COVID-19, and Lyme disease vaccines at IDWeek 2026. Key studies include Phase 3 results for Lyme vaccine LB6V and real-world effectiveness data for ABRYSVO and PREVNAR 20.